Last mentioned: Mar 16, 2026
Rollout Milestone
Acoziborole enters the final stages of regulatory rollout for endemic regions.
Trial Results
Phase 2/3 clinical trial results for Acoziborole show high efficacy.
Fexinidazole Approval
First all-oral 10-day treatment for sleeping sickness is approved.
Research Begins
DNDi starts screening compounds for a single-dose HAT treatment.
The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.
This page surfaces every story mentioning Drugs for Neglected Diseases initiative (DNDi) across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Drugs for Neglected Diseases initiative (DNDi) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |